Yuko Mizuma – GM, Hong Kong & Macau, Eli Lilly Asia, Inc.
Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses…
At Sanwa BioTech, we believe that impending changes are coming to the way to conventional clinical diagnostic & academic R&D for bio-discoveries. We aim to become a driving force for these changes to revolutionize healthcare solutions into the future. Sanwa BioTech delivers accurate and actionable information through our disposable Lab-On-Chip (LOC) rapid diagnostic platform, resulting in transformative diagnostic tests for faster clinical decisions and better economic outcomes.
At Sanwa Biotech, we provide diagnostic solutions based on our microfluidic disposable Lab-On-Chip (LOC) platform, including an integrative point of care device, reagents, software analytics & data management service, which brings convenience and value in diseases monitoring and supports clinical decisions, improves patients health and contributes to innovative solutions that combat challenges on global health care.
Contact
Unit 627, 6/F, BioTech Centre Two,
No.11 Science Park West Avenue,
Hong Kong Science Park,
Shatin, Hong Kong SAR,
CHINA
Unit 2, 5/F.,
Wah Lai Industrial Centre,
10-14 Kwei Tei Street,
Fo Tan, Hong Kong SAR,
CHINA
Tel: +852 2698 9903
Website: http://sanwabiotech.com/en/index.html
Email: inquiry@sanwabiotech.com
Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses…
Drawing on an extensive management background in telecom, IT, and digital, Vincent Ma now serves as CEO of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP). He outlines the under-construction…
Johnson & Johnson Innovative Medicine veteran and general manager of the company’s Hong Kong & Macau affiliate SunKeun Huh explains J&J Hong Kong’s strong position in schizophrenia and its significant oncology…
OASES was established to position Hong Kong as a global innovation and technology hub, with significant investments in infrastructure and funding, particularly focusing on life and health sciences, AI, fintech,…
One year since our last conversation, the Hong Kong Institute of Biotechnology’s Gina Jiang introduces the significant strides made in setting up a GMP facility for CAR-T cell therapy manufacturing…
A surgeon by training, Prof Philip Chiu is now dean of the Faculty of Medicine at the research-focused Chinese University of Hong Kong (CUHK). He shares the creation of CUHK’s…
The City University of Hong Kong (CityUHK) has a well-earned reputation as an innovative hub for research and professional education. Michael Yang, Senior VP of Innovation and Enterprise, professor of…
Andrea Chang, general manager of Eisai Hong Kong explains the importance of the firm’s FDA-approved Biogen-partnered Alzheimer’s disease (AD) product, particularly in Hong Kong where some 20 percent of the…
Dr Juliana Chan, one of Asia’s leading endocrinologists, is also the founding director of GemVCare, a company that provides data to medical professionals to advise patients on diabetes prevention, diagnosis, and…
Immuno Cure has a unique approach to the failure-ridden field of HIV vaccine development: focusing on a therapeutic vaccine for already infected individuals rather than a preventive vaccine. Founders Tom…
Arbele is a clinical stage biotech centred on an innovative T-Cell Engager approach to gastrointestinal cancers. Chairman and founder John Luk explains the prevalence of these cancers in China, the…
Sabrina Chan, senior executive director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI), an organization that represents the innovative pharmaceutical industry in Hong Kong and Macau, weighs in…
See our Cookie Privacy Policy Here
